Nutrition News

Chronic kidney disease patients who consumed diets high in animal protein were three times more likely to develop kidney failure in a study than patients who consumed diets high in fruits and vegetables, according to research published in the Journal of the American Society of Nephrology.

This publication was developed under Contract Number HHSM-500-2013-NW002C, titled “End Stage Renal Disease Network Coordinating Center (ESRD NCC)", sponsored by the Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services. The contents presented do not necessarily reflect CMS policy.

Diets with a high acid content may increase chronic kidney disease patients' risk of developing kidney failure. The finding, which comes from a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), suggests that patients may want to limit their intake of meats and increase their consumption of fruits and vegetables to help protect their kidneys.

Researchers presented two preliminary studies at ASN Kidney Week 2014 that demonstrate the potential of tenapanor—a minimally-systemic inhibitor of the intestinal sodium/proton exchanger subtype 3 (NHE3)—to help reduce phosphorus absorption in patients with kidney disease.

PHILADELPHIA – Among 200 patients on dialysis, extending weekly dialysis hours for 12 months did not improve quality of life, but was linked with improvements in some laboratory measures, such as potassium and phosphate blood levels, and a reduced need for blood pressure medications.

The National Kidney Foundation has launched a new app and website, called My Food Coach, that allows people to customize meal plans based on food preferences and/or chronic conditions such as kidney disease, diabetes, and heart disease.

Renal dietitian Peggy Harum RD, LD, has received the 2013–2014 Outstanding Service Award from the Renal Practice Groupof the Academy of Nutrition and Dietetics (AND).

The price of Keryx Biopharmaceuticals Inc.’s stock has dropped almost $4 a share since last week over what the company said was a misinterpretation by investors of a label indication to its new phosphate binder.

Keryx Biopharmaceuticals Inc. said today that it received U.S. Food and Drug Administration approval for ferric citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with end-stage renal disease.

Keryx Biopharmaceuticals' Zerenex (ferric citrate) may reduce dialysis patients' need to take multiple drugs to reduce serum phosphorus, raise iron stores and reduce intravenous iron and erythropoietin-stimulating agents usage, according to Phase 3 clinical trial results published in the Journal of the American Society of Nephrology.